FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1486074920> ?p ?o ?g. }

• W1486074920 endingPage "214" @default.
• W1486074920 startingPage "210" @default.
• W1486074920 abstract "Recurrent type I endometrial cancer (EC) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic cancer patients treated with bevacizumab may also take metformin, whether metformin modulates response to anti-VEGF therapy has not yet been investigated. Here, we report the case of a patient with advanced EC treated, among other drugs, with bevacizumab in combination with metformin. The patient affected by relapsed EC G3 type 1, presented in march 2010 with liver, lungs and mediastinic metastases. After six cycles of paclitaxel and cisplatin she underwent partial response. Later on, she had disease progression notwithstanding administration of multiple lines of chemotherapy. In march 2013, due to brain metastases with coma, she began steroid therapy with development of secondary diabetes. At this time, administration of Bevacizumab plus Metformin improved her performance status. CT scans performed in this time window showed reduced radiologic density of the lung and mediastinic lesions and of liver disease, suggestive of increased tumor necrosis. Strong (18)F-FDG uptake by PET imaging along with high levels of monocarboxylate transporter 4 and lack of liver kinase B1 expression in liver metastasis, highlighted metabolic features previously associated with response to anti-VEGF therapy and phenformin in preclinical models. However, clinical benefit was transitory and was followed by rapid and fatal disease progression. These findings--albeit limited to a single case--suggest that tumors lacking LKB1 expression and/or endowed with an highly glycolytic phenotype might develop large necrotic areas following combined treatment with metformin plus bevacizumab. As metformin is widely used among diabetes patients as well as in ongoing clinical trials in cancer patients, these results deserve further clinical investigation." @default.
• W1486074920 created "2016-06-24" @default.
• W1486074920 creator A5016984915 @default.
• W1486074920 creator A5019015189 @default.
• W1486074920 creator A5026589555 @default.
• W1486074920 creator A5032866888 @default.
• W1486074920 creator A5055109336 @default.
• W1486074920 creator A5064152080 @default.
• W1486074920 creator A5065697790 @default.
• W1486074920 creator A5065746326 @default.
• W1486074920 date "2015-01-21" @default.
• W1486074920 modified "2023-09-29" @default.
• W1486074920 title "Metformin: a modulator of bevacizumab activity in cancer? A case report" @default.
• W1486074920 cites W1970614140 @default.
• W1486074920 cites W1974496331 @default.
• W1486074920 cites W2020993937 @default.
• W1486074920 cites W2036768908 @default.
• W1486074920 cites W2054770163 @default.
• W1486074920 cites W2071944097 @default.
• W1486074920 cites W2093294518 @default.
• W1486074920 cites W2106285227 @default.
• W1486074920 cites W2135617839 @default.
• W1486074920 cites W2136603217 @default.
• W1486074920 cites W2146511561 @default.
• W1486074920 cites W2146654374 @default.
• W1486074920 cites W2154516141 @default.
• W1486074920 doi "https://doi.org/10.1080/15384047.2014.1002366" @default.
• W1486074920 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4623111" @default.
• W1486074920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25607951" @default.
• W1486074920 hasPublicationYear "2015" @default.
• W1486074920 type Work @default.
• W1486074920 sameAs 1486074920 @default.
• W1486074920 citedByCount "13" @default.
• W1486074920 countsByYear W14860749202015 @default.
• W1486074920 countsByYear W14860749202017 @default.
• W1486074920 countsByYear W14860749202018 @default.
• W1486074920 countsByYear W14860749202019 @default.
• W1486074920 countsByYear W14860749202021 @default.
• W1486074920 countsByYear W14860749202022 @default.
• W1486074920 countsByYear W14860749202023 @default.
• W1486074920 crossrefType "journal-article" @default.
• W1486074920 hasAuthorship W1486074920A5016984915 @default.
• W1486074920 hasAuthorship W1486074920A5019015189 @default.
• W1486074920 hasAuthorship W1486074920A5026589555 @default.
• W1486074920 hasAuthorship W1486074920A5032866888 @default.
• W1486074920 hasAuthorship W1486074920A5055109336 @default.
• W1486074920 hasAuthorship W1486074920A5064152080 @default.
• W1486074920 hasAuthorship W1486074920A5065697790 @default.
• W1486074920 hasAuthorship W1486074920A5065746326 @default.
• W1486074920 hasBestOaLocation W14860749201 @default.
• W1486074920 hasConcept C121608353 @default.
• W1486074920 hasConcept C126322002 @default.
• W1486074920 hasConcept C143998085 @default.
• W1486074920 hasConcept C2776256026 @default.
• W1486074920 hasConcept C2776694085 @default.
• W1486074920 hasConcept C2776999253 @default.
• W1486074920 hasConcept C2777688063 @default.
• W1486074920 hasConcept C2777701055 @default.
• W1486074920 hasConcept C2777802072 @default.
• W1486074920 hasConcept C2778877718 @default.
• W1486074920 hasConcept C2779013556 @default.
• W1486074920 hasConcept C2779306644 @default.
• W1486074920 hasConcept C2780323712 @default.
• W1486074920 hasConcept C2780394083 @default.
• W1486074920 hasConcept C2781433595 @default.
• W1486074920 hasConcept C71924100 @default.
• W1486074920 hasConceptScore W1486074920C121608353 @default.
• W1486074920 hasConceptScore W1486074920C126322002 @default.
• W1486074920 hasConceptScore W1486074920C143998085 @default.
• W1486074920 hasConceptScore W1486074920C2776256026 @default.
• W1486074920 hasConceptScore W1486074920C2776694085 @default.
• W1486074920 hasConceptScore W1486074920C2776999253 @default.
• W1486074920 hasConceptScore W1486074920C2777688063 @default.
• W1486074920 hasConceptScore W1486074920C2777701055 @default.
• W1486074920 hasConceptScore W1486074920C2777802072 @default.
• W1486074920 hasConceptScore W1486074920C2778877718 @default.
• W1486074920 hasConceptScore W1486074920C2779013556 @default.
• W1486074920 hasConceptScore W1486074920C2779306644 @default.
• W1486074920 hasConceptScore W1486074920C2780323712 @default.
• W1486074920 hasConceptScore W1486074920C2780394083 @default.
• W1486074920 hasConceptScore W1486074920C2781433595 @default.
• W1486074920 hasConceptScore W1486074920C71924100 @default.
• W1486074920 hasIssue "2" @default.
• W1486074920 hasLocation W14860749201 @default.
• W1486074920 hasLocation W14860749202 @default.
• W1486074920 hasLocation W14860749203 @default.
• W1486074920 hasLocation W14860749204 @default.
• W1486074920 hasLocation W14860749205 @default.
• W1486074920 hasOpenAccess W1486074920 @default.
• W1486074920 hasPrimaryLocation W14860749201 @default.
• W1486074920 hasRelatedWork W1486074920 @default.
• W1486074920 hasRelatedWork W2003064295 @default.
• W1486074920 hasRelatedWork W2070470195 @default.
• W1486074920 hasRelatedWork W2086442829 @default.
• W1486074920 hasRelatedWork W2088411588 @default.
• W1486074920 hasRelatedWork W2123409499 @default.
• W1486074920 hasRelatedWork W2734035737 @default.
• W1486074920 hasRelatedWork W2954093073 @default.

• next